Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides

Thrombosis Research

Volumn 98, Issue 1, 2000, Pages 73-81

  Muehlenweg, Bernd ^a   Guthaus, Elke ^a,b   De Prada, Nuria Arroyo ^a   Schmitt, Manfred ^a   Schmiedeberg, Niko ^b   Kotzsch, Matthias ^c   Creutzburg, Sabine ^a   Kramer, Michael D ^d   Kessler, Horst ^b   Wilhelm, Olaf G ^a,e   Magdolen, Viktor ^a  

^a Frauenklinik   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Wilex Biotechnology GmbH   (Germany)

Author keywords

Chimera; Monoclonal antibodies; Plasminogen activator inhibitor type 1; Synthetic peptides

Indexed keywords

MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SYNTHETIC PEPTIDE;

ARTICLE; CHIMERA; EPITOPE MAPPING; HUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; EPITOPE MAPPING; HUMANS; IMMUNODOMINANT EPITOPES; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECOMBINANT FUSION PROTEINS;

EID: 0033997385     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00238-8     Document Type: Article

References (37)

1. Andreasen P.A., Kjøller L., Christensen L., Duffy M.J. The urokinase-plasminogen activator system in cancer metastasis. A review. Int J Cancer. 72:1997;1-22.
2. Andreasen P.A., Riccio A., Welinder K.G., Douglas R., Sartorio R., Nielsen L.S., Oppenheimer C., Blasi D., Danø K. Plasminogen activator inhibitor type-1. Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing FEBS Lett. 209:1986;213-218.
3. Mottonen J., Goldsmith E.J. Structural basis of latency in PAI-1. Nature. 355:1992;270-273.
4. Aertgeerts K., De Bondt H.L., De Ranter C.J., Declerck P.J. Mechanisms contributing to the conformational and functional flexibility of PAI-1. Nat Struct Biol. 2:1995;891-897.
5. Berkenpas M.B., Lawrence D.A., Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14:1995;2969-2977.
6. Sharp A.M., Stein P.E., Pannu N.S., Carrell R.W., Berkenpas M.B., Ginsburg D., Lawrence D.A., Read R.J. The active conformational of PAI-1, a target for drugs to control fibrinolysis and cell adhesion. Structure. 7:1999;111-118.
7. Huber R., Carrell R.W. Implications of the three-dimensional structure of alpha1-anti-trypsin for structure and function of serpins. Biochemistry. 28:1989;8951-8966.
8. Kruithof E.K., Baker M.S., Bunn C.L. Biological and clinical aspects of plasminogen activator type-2. Blood. 86:1995;4007-4024.
9. Harrop S.J., Jankova L., Coles M., Jardine D., Whittaker J.S., Gould A.R., Meister A., King G.C., Mabbutt B.C., Curmi P.M. The crystal structure of plasminogen activator inhibitor 2 at 2.0 Å resolution. Implications for serpin function Structure. 7:1999;43-54.
10. Sprengers E.D., Kluft C. Plasminogen activator inhibitors. Blood. 69:1987;381-387.
11. Loskutoff D.J., Curriden S.A., Hu G., Deng G. Regulation of cell adhesion by PAI-1. APMIS. 107:1999;54-61.
12. Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type plasminogen activator and the tissue-type plasminogen activator and of the inhibitor PAI-1 in breast cancer. Semin Thromb Hemost. 17:1991;303-312.
13. Bajou K., Noël A., Gerard R.D., Masson V., Brünner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M. Absence of host PAI-1 prevents cancer invasion and vascularization. Nat Med. 4:1998;923-928.
14. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Höfler H., Jänicke F., Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis. Prognostic relevance and target for therapy Thromb Haemost. 78:1997;285-296.
15. Horn L.C., Emmrich P., Bilek K. The early placental trophoblast. Normal development and endometrial and non-tumor-induced disorders. Zentralbl Gynakol. 118:1996;487-497.
16. Ehrlich H.J., Gebbink R.K., Preissner K.T. Thrombin neutralizes plasminogen activator inhibitor type-1 that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol. 155:1991;1773-1781.
17. Shen G.X. Vascular cell-derived fibrinolytic atherothrombotic vascular disorder. Int J Mol Med. 1:1998;399-408.
18. Eitzmann D.T., Ginsburg D. Of mice and men. The function of plasminogen activators inhibitors (PAIs) in vivo. Adv Exp Med Biol. 425:1997;131-141.
19. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., Schmitt M. Multifunctional potential of the plasminogen system in tumor invasion and metastasis. Int J Oncol. 13:1998;893-906.
20. Kanse S.M., Kost C., Wilhelm O.G., Andreasen P.A., Preissner K.T. The urokinase receptor is a major vitronectin-binding protein in endothelial cells. Exp Cell Res. 224:1996;344-353.
21. Kjøller L., Kanse S.M., Kirkegaard T., Rodenburg K.W., Ronne E., Goodman S.L., Preissner K.T., Ossowski L., Andreasen P.A. PAI-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 232:1997;420-429.
22. Ehrlich H.J., Keijer J., Preissner K.T., Klein Gebbink R., Pannekoek H. Functional interaction of PAI-1 and heparin. Biochemistry. 30:1991;1021-1028.
23. Hoylaerts M., Rijken D.C., Lijnen H.R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 257:1982;2912-2919.
24. Antalis T.M., Clark M.A., Barnes T., Lehrbach P.R., Devine P.L., Schevzov G., Goss N.H., Stephens R.W., Tolstoshev P. Cloning and expression of a cDNA coding for human monocyte derived plasminogen activator inhibitor. Proc Natl Acad Sci USA. 85:1988;985-989.
25. Türkmen B., Schmitt M., Schmalfeldt B., Trommler P., Hell W., Creutzburg S., Graeff H., Magdolen V. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis. 18:1997;686-689.
26. Carpino L.A., Han G.Y. The fluorenylmethoxycarbonyl amino-protecting group. J Org Chem. 37:1972;3404-3409.
27. Fields G.B., Noble R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxy-carbonyl amino acids. Int J Pept Protein Res. 35:1990;161-214.
28. Carrell R.W., Stein P.E. The biostructural pathology of the serpins. Critical function of sheet opening mechanism Biol Chem Hoppe Seyler. 377:1996;1-17.
29. Ehrlich H.J., Klein Gebbink R., Keijer J., Pannekoek H. Elucidation of structural requirements on PAI-1 for binding to heparin. J Biol Chem. 267:1992;11606-11611.
30. Padmanabhan J., Sane D.C. Localization of a vitronectin binding region on PAI-1. Thromb Haemost. 73:1995;829-834.
31. Keijer J., Linders M., van Zonneveld A.J., Ehrlich H.J., de Boer J.P., Pannekoek H. The interaction of PAI-1 with plasminogen activators (tissue-type and urokinase-type) and fibrin. Localization of interaction sites and physiological relevance Blood. 78:1991;401-409.
32. Debrock S., Declerck P.J. Characterization of common neoantigenic epitopes generated in PAI-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases. FEBS Lett. 376:1995;243-246.
33. Debrock S., Declerck P.J. Identification of a functional epitope in PAI-1, not localized in the reactive center loop. Thromb Haemost. 79:1998;597-601.
34. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:1994;526-529.
35. McCarthy B.J., Worrall D.M. Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins. J Mol Biol. 267:1997;561-569.
36. Grasberger H., Büttner C., Janssen O.E. Modularity of serpins. A bifunctional chimera possessing alpha1-proteinase inhibitor and thyroxine-binding globulin properties J Biol Chem. 274:1999;15046-15051.
37. Luther T., Magdolen V., Albrecht S., Kasper M., Riemer C., Kessler H., Graeff H., Müller M., Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Path. 150:1997;1231-1244.